Supernus Pharmaceuticals Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. We're going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thank you for joining us day one of our London conference. It's my pleasure to have Jack Khattar, CEO of Supernus.
Welcome, Jack. Thank you. Thanks for having me.
Big changes going on this year for you, Jack. There are some people who may be revisiting the story, so could you kind of give us the latest and greatest about Supernus and your priorities over the next year?
Yeah, sure. Thank you for being here. Just quick reminder, I'll be making forward-looking statements, so please check our SEC filings for all the risk factors associated with the business. This is actually a very exciting time for us at Supernus. We just completed the merger with Indivior Pharmaceuticals. On a pro forma basis that we had communicated when we announced the merger, you're looking at a company of about $2.2 billion in revenue and a fairly healthy adjusted EBITDA of north of $800 million. So it's a very substantial business. We're focused on CNS. The primary therapeutic areas are addiction, opioid use disorder, specifically SUBLOCADE, which is the leading product in that space. Then Qelbree, which is for ADHD as a leading novel non-stimulant in that space. ZURZUVAE, which is the only product approved actually for postpartum depression.
It's been a great product in partnership with Biogen. Also we have a healthy Parkinson's franchise, primarily with ONAPGO, which is the only apomorphine infusion device that we launched about a year and a half ago, together with GOCOVRI, which is the only Parkinson's product approved for off episodes and dyskinesia. So we have a really nice collection of products that are growth products that should get us well into the 2030 and beyond that. In addition to that, we have a nice pipeline also of couple products in Phase 2b, one which is a unique epilepsy product, SPN-817, and then SPN-820, which is a first-in-class depression program that we have also going on. Very healthy balance sheet. After the merger close, we have leverage which is less than 1x, so we have a tremendous financial flexibility and capacity to continue to do some of the things we've done historically by bringing products from the outside as well funding our own R&D activities.
Mm. Congratulations on the progress. With the merger of equals done with Indivior, are you the one who drives all the decisions? When we think about guidance, you issuing new guidance, spending on this program, is it your decision or how does this all work?
Well, I mean, we're one team right now, so we are Supernus. It doesn't matter where you came from as an employee, we're all Supernus employees as one team, one company. The leadership team came mainly from Supernus. We had a couple members who came from Indivior side, but at the end of the day, we're now the new Supernus, so to speak, and we all manage the company as one team and one company.
Understood. When you report Q4 earnings, is that the time we can expect you to issue new 2027 guidance with the SUBLOCADE and Indivior products, or is it JP Morgan?
Yeah, I mean, typically we don't pre-announce our historic practice, so to speak. We don't pre-announce around the JP Morgan. I think we'll follow the same path in a way. We'll issue the guidance in February around the earnings, yeah, for 2027.
This year, with your 2026 guidance, you're helpful in breaking out certain individual product guidance. Is that something you would entertain in 2027, ONAPGO, Indivior products, for instance?
We are looking at it now. I mean, realizing, of course, we're a much bigger company. We have some really key important products. Now, historically, we did it only in few occasions when necessary. For example, of course, ONAPGO, because of the supply situation, we had to give people at least a bracket, the situation for them for 2026. Same thing, we did that on Trokendi XR, Oxtellar XR when they went generic, so that we can isolate the growth products from the legacy products. So remains to be seen. We are looking at it, see if we can be as helpful as possible, but typically I'm against having to get into the minutia of every single product, especially when you have 11 products now in the portfolio.
Right. Okay. I personally get EBITDA 2027 year end, or 27 of like $1.1 billion. To grow that EBITDA conceptually, for 2027, are you spending more to drive more top line growth, or is this kind of, in terms of the expense structure, this is pretty good on the SG&A front?
Yeah, I mean, our priorities moving forward is, the first thing is our existing growth products. We did mention several times that we're going to continue to invest behind clearly SUBLOCADE, Qelbree, ONAPGO, ZURZUVAE, and to a much lesser degree, GOCOVRI, of course. So that's really our primary top priority, make sure these products are maxed out as far as the growth potential behind them, and we have a long runway on pretty much all of them. The second priority is, of course, continue to advance our pipeline and the development of our products that are currently in the phase II stage. Then we will continue, and we are always active on the BD front, in bringing other products and other opportunities for the company.
Now, at the same time, of course, we realize we are a bigger company, much bigger scale, a lot of cash generation, so we will continue to look at also a balanced approach, maybe from a capital allocation perspective. I know a lot of folks have asked me about share buyback and so forth. I mean, all these are under consideration and will be considered to do the best for our shareholders. But I do remind people also, we are in the pharma business. Pharma business, you always need more products, you always need more products that come in either internally or from the outside. So we got to balance all that, obviously, as time goes on.
Okay, very clear. In terms of BD, you mentioned you're less than one times your leverage. How high can you go, and how much firepower do you think you'll have come, say, year end of 2027?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
